Retinal Vein Occlusion

• 

  Subject Areas on Research

  • A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection. 
  • AMBULATORY BLOOD PRESSURE PATTERNS IN PATIENTS WITH RETINAL VEIN OCCLUSION. 
  • Aflibercept for central retinal vein occlusion: an ongoing revolution or are we spinning in place? 
  • Aldosterone Exposure Causes Increased Retinal Edema and Severe Retinopathy Following Laser-Induced Retinal Vein Occlusion in Mice. 
  • Antithrombotic effect of ticlopidine in an experimental model of retinal vein occlusion. 
  • Are microvascular abnormalities in the retina associated with depression symptoms? The Cardiovascular Health Study. 
  • Arteriovenous sheathotomy for branch retinal vein occlusion. 
  • Asymmetric retinopathy in patients with diabetes mellitus. 
  • Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4. 
  • Best practices for treatment of retinal vein occlusion. 
  • Body mass index and vein occlusion. 
  • Branch retinal vein occlusion and optic nerve head topographic parameters: the Singapore Indian eye study. 
  • CENTRAL RETINAL VEIN OCCLUSION IN GATA2 DEFICIENCY. 
  • Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. 
  • Central retinal vein occlusion in patients treated with long-term warfarin sodium (Coumadin) for anticoagulation. 
  • Chorioretinal venous anastomosis for central retinal vein occlusion: transvitreal venipuncture. 
  • Choroidal Changes After Suprachoroidal Injection of Triamcinolone Acetonide in Eyes With Macular Edema Secondary to Retinal Vein Occlusion. 
  • Clinical practice. Retinal-vein occlusion. 
  • Combination therapy for macular edema secondary to retinal vein occlusion. 
  • Combined central retinal vein and artery occlusion associated with an isolated superior ophthalmic vein thrombosis. 
  • Controversy in the management of retinal venous occlusive disease. 
  • Current concepts in the management of central retinal vein occlusion. 
  • Current concepts in the management of central retinal vein occlusion. 
  • Diagnostic and Therapeutic Challenges. 
  • Diagnostic and therapeutic challenges. 
  • Differential effects of triamcinolone and bevacizumab in central retinal vein occlusion. 
  • Direct medical costs and resource use for treating central and branch retinal vein occlusion in commercially insured working-age and Medicare populations. 
  • Does radial optic neurotomy alter retinal blood flow in eyes with a central retinal vein occlusion? 
  • Effect of oral pentoxifylline on cystoid macular edema associated with central retinal vein occlusion. 
  • Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. 
  • Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned? 
  • Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. 
  • Fundus photographic, fluorescein angiographic, and indocyanine green angiographic signs in successful laser chorioretinal venous anastomosis for central retinal vein occlusion. 
  • Hemi-retinal vein occlusion following LASIK. 
  • Homocysteine and retinal emboli: the Blue Mountains Eye Study. 
  • Homocysteine and retinal vein occlusion: a population-based study. 
  • Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. 
  • Interventions for branch retinal vein occlusion: an evidence-based systematic review. 
  • Interventions for central retinal vein occlusion: an evidence-based systematic review. 
  • Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment. 
  • Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. 
  • Intravitreal tissue plasminogen activator for the treatment of central retinal vein occlusion. 
  • Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. 
  • Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. 
  • Intravitreal triamcinolone for cystoid macular edema related to branch retinal vein occlusion. 
  • Ischemic central retinal vein occlusion and retinitis pigmentosa: lower risk of neovascularization? 
  • Laser chorioretinal venous anastomosis for nonischemic central retinal vein occlusion. 
  • Laser-induced chorioretinal anastomosis and central retinal vein occlusion. 
  • Laser-induced chorioretinal venous anastomosis for nonischemic central or branch retinal vein occlusion. 
  • Macroaneurysms associated with retinal branch vein occlusion. 
  • Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. 
  • Natural history of branch retinal vein occlusion: an evidence-based systematic review. 
  • Natural history of central retinal vein occlusion: an evidence-based systematic review. 
  • Optic nerve sheath decompression for progressive central retinal vein occlusion. 
  • Optimal laser power to rupture Bruch's membrane and the retinal vein in the pig. 
  • Pars plana vitrectomy, internal limiting membrane peeling, and panretinal endophotocoagulation for macular edema secondary to central retinal vein occlusion. 
  • Patchy ischemic retinal whitening in acute central retinal vein occlusion. 
  • Photochemical initiation of thrombosis. Fluorescein angiographic, histologic, and ultrastructural alterations in the choroid, retinal pigment epithelium, and retina. 
  • Photodynamic retinal vascular thrombosis. Rate and duration of vascular occlusion. 
  • Plasma endothelial-1 concentrations in patients with retinal vein occlusions. 
  • Plasma endothelin-1 concentrations in patients with retinal vein occlusions. 
  • Postmarketing analysis of aflibercept-related sterile intraocular inflammation. 
  • Prevalence and risk factors of retinal vein occlusion in an Asian population. 
  • Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results. 
  • Radial optic neurotomy as treatment for central retinal vein occlusion. 
  • Radial optic neurotomy as treatment for central retinal vein occlusion. 
  • Radial optic neurotomy in retinal vein occlusion. 
  • Radial optic neurotomy in the porcine eye without retinal vein occlusion. 
  • Rapid regression of retinal neovascularization following intravitreal bevacizumab in branch retinal vein occlusion imaged by optical coherence tomography angiography. 
  • Reading speed improvements in retinal vein occlusion after ranibizumab treatment. 
  • Recombinant tissue plasminogen activator injected into the vitreous cavity may penetrate the retinal veins of a porcine model of vascular occlusion. 
  • Resource use and costs of branch and central retinal vein occlusion in the elderly. 
  • Retinal Vein Occlusion in a Multi-Ethnic Asian Population: The Singapore Epidemiology of Eye Disease Study. 
  • Retinal vein occlusion after trabeculectomy with mitomycin C. 
  • Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. 
  • Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. 
  • Retinal vein occlusion: beyond the acute event. 
  • Retinal vein occlusions in patients taking warfarin. 
  • Retinal venous occlusion associated with depot medroxyprogesterone acetate. 
  • SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design. 
  • SCORE Study report 3: study design and baseline characteristics. 
  • Sequential Sterile Intraocular Inflammation Associated With Consecutive Intravitreal Injections of Aflibercept and Ranibizumab. 
  • The effect of arteriovenous sheathotomy on cystoid macular oedema secondary to branch retinal vein occlusion. 
  • The natural history of retinal vein occlusion: what do we really know? 
  • The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. 
  • The risk of missing angle neovascularization by omitting screening gonioscopy in acute central retinal vein occlusion. 
  • Therapies for Macular Edema Associated with Branch Retinal Vein Occlusion: A Report by the American Academy of Ophthalmology. 
  • Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. 
  • Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. 
  • Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. 
  • Vitrectomy prevents retinal hypoxia in branch retinal vein occlusion. 
  • Vitreous Hemorrhage complicating laser-induced chorioretinal anastomosis for central retinal vein occlusion. 
• 

  Keywords of People

  • Fekrat, Sharon, Professor of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • Mruthyunjaya, Prithvi, Adjunct Associate Professor in the Department of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Toth, Cynthia Ann, Joseph A.C. Wadsworth Professor of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery